Jangsoon Lee1,2, Bora Lim1,2, Troy Pearson1, Kuicheon Choi1, Jon A Fuson1, Chandra Bartholomeusz1,2, Linda J Paradiso3, Thomas Myers3, Debu Tripathy1, Naoto T Ueno4,5. 1. Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA. 3. Spirita Oncology, LLC, Natick, MA, USA. 4. Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. nueno@mdanderson.org. 5. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA. nueno@mdanderson.org.
Abstract
PURPOSE: Triple-negative breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus, it does not respond to receptor-targeted treatments. TNBC has higher recurrence, metastasis, and mortality rates than other subtypes of breast cancer. Mounting data suggest that the MAPK (also known as RAS-RAF-MEK-ERK) pathway is an important therapeutic target in TNBC. METHODS: To evaluate anti-tumor and anti-metastasis efficacy of E6201, we used cell proliferation assay, soft agar assay, cell cycle assay, Annexin V staining assay, immunoblotting analysis, immunohistochemistry, migration assay, invasion assay, mammary fat pad xenograft, and experimental and spontaneous metastasis xenograft models. We also evaluated the anti-tumor efficacy of E6201 plus CDK4/6 inhibitor, mTOR inhibitor, or ATR inhibitor. RESULTS: E6201 inhibited TNBC cell colony formation, migration, and invasion in a dose-dependent manner. E6201 induced G1 cell cycle arrest and apoptosis. E6201 inhibited TNBC xenograft growth and inhibited TNBC lung metastasis and improved mouse survival in experimental metastasis and spontaneous metastasis assays. Immunohistochemical staining demonstrated that E6201 decreased the metastatic burden in the lung and decreased phosphorylated ERK expression in a dose-dependent manner. Combination of E6201 with CDK4/6 inhibitor or mTOR inhibitor enhanced E6201's in vitro anti-tumor efficacy. CONCLUSION: These results indicate that E6201 exhibits anti-tumor efficacy against TNBC in vitro and anti-metastasis efficacy against TNBC in vivo. These results provide a rationale for further clinical development of E6201 as a MAPK-pathway-targeted therapy for TNBC.
PURPOSE: Triple-negative breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and humanepidermal growth factor receptor 2, and thus, it does not respond to receptor-targeted treatments. TNBC has higher recurrence, metastasis, and mortality rates than other subtypes of breast cancer. Mounting data suggest that the MAPK (also known as RAS-RAF-MEK-ERK) pathway is an important therapeutic target in TNBC. METHODS: To evaluate anti-tumor and anti-metastasis efficacy of E6201, we used cell proliferation assay, soft agar assay, cell cycle assay, Annexin V staining assay, immunoblotting analysis, immunohistochemistry, migration assay, invasion assay, mammary fat pad xenograft, and experimental and spontaneous metastasis xenograft models. We also evaluated the anti-tumor efficacy of E6201 plus CDK4/6 inhibitor, mTOR inhibitor, or ATR inhibitor. RESULTS:E6201 inhibited TNBC cell colony formation, migration, and invasion in a dose-dependent manner. E6201 induced G1 cell cycle arrest and apoptosis. E6201 inhibited TNBC xenograft growth and inhibited TNBC lung metastasis and improved mouse survival in experimental metastasis and spontaneous metastasis assays. Immunohistochemical staining demonstrated that E6201 decreased the metastatic burden in the lung and decreased phosphorylated ERK expression in a dose-dependent manner. Combination of E6201 with CDK4/6 inhibitor or mTOR inhibitor enhanced E6201's in vitro anti-tumor efficacy. CONCLUSION: These results indicate that E6201 exhibits anti-tumor efficacy against TNBC in vitro and anti-metastasis efficacy against TNBC in vivo. These results provide a rationale for further clinical development of E6201 as a MAPK-pathway-targeted therapy for TNBC.
Entities:
Keywords:
E6201; MAPK pathway; MEK inhibitor; Metastasis; Triple-negative breast cancer
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Klaus P Hoeflich; Carol O'Brien; Zachary Boyd; Guy Cavet; Steve Guerrero; Kenneth Jung; Tom Januario; Heidi Savage; Elizabeth Punnoose; Tom Truong; Wei Zhou; Leanne Berry; Lesley Murray; Lukas Amler; Marcia Belvin; Lori S Friedman; Mark R Lackner Journal: Clin Cancer Res Date: 2009-06-30 Impact factor: 12.531
Authors: John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544
Authors: Jennifer H Law; Golareh Habibi; Kaiji Hu; Hamid Masoudi; Michelle Y C Wang; Anna L Stratford; Eugene Park; Julia M W Gee; Pauline Finlay; Helen E Jones; Robert I Nicholson; Joan Carboni; Marco Gottardis; Michael Pollak; Sandra E Dunn Journal: Cancer Res Date: 2008-12-15 Impact factor: 12.701
Authors: Olga K Mirzoeva; Debopriya Das; Laura M Heiser; Sanchita Bhattacharya; Doris Siwak; Rina Gendelman; Nora Bayani; Nicholas J Wang; Richard M Neve; Yinghui Guan; Zhi Hu; Zachary Knight; Heidi S Feiler; Philippe Gascard; Bahram Parvin; Paul T Spellman; Kevan M Shokat; Andrew J Wyrobek; Mina J Bissell; Frank McCormick; Wen-Lin Kuo; Gordon B Mills; Joe W Gray; W Michael Korn Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: Mothaffar F Rimawi; Priya B Shetty; Heidi L Weiss; Rachel Schiff; C Kent Osborne; Gary C Chamness; Richard M Elledge Journal: Cancer Date: 2010-03-01 Impact factor: 6.860
Authors: Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt Journal: J Clin Oncol Date: 2008-04-07 Impact factor: 44.544
Authors: Yaron Vinik; Francisco Gabriel Ortega; Gordon B Mills; Yilling Lu; Menucha Jurkowicz; Sharon Halperin; Mor Aharoni; Mordechai Gutman; Sima Lev Journal: Sci Adv Date: 2020-10-02 Impact factor: 14.136
Authors: Lars Hanker; Frank Köster; Karen Bräutigam; Elodie Kabore-Wolff; Ahmad Fawzi Hussain; Stephan Polack; Achim Rody Journal: J Cancer Res Clin Oncol Date: 2021-06-29 Impact factor: 4.553